Fractyl Health (NASDAQ:GUTS – Get Free Report) and Plus Therapeutics (NASDAQ:PSTV – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Earnings & Valuation
This table compares Fractyl Health and Plus Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Fractyl Health | $90,000.00 | 748.76 | -$68.69 million | ($2.06) | -0.65 |
Plus Therapeutics | $5.82 million | 11.90 | -$12.98 million | ($2.24) | -0.31 |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Fractyl Health and Plus Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Fractyl Health | 1 | 0 | 4 | 0 | 2.60 |
Plus Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Fractyl Health currently has a consensus price target of $6.90, suggesting a potential upside of 414.93%. Plus Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 1,046.13%. Given Plus Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Fractyl Health.
Volatility and Risk
Fractyl Health has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
Institutional and Insider Ownership
3.3% of Plus Therapeutics shares are owned by institutional investors. 26.1% of Fractyl Health shares are owned by insiders. Comparatively, 0.8% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Fractyl Health and Plus Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Fractyl Health | N/A | -584.35% | -102.88% |
Plus Therapeutics | -357.85% | N/A | -117.72% |
Summary
Plus Therapeutics beats Fractyl Health on 8 of the 14 factors compared between the two stocks.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
About Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.